Stoke Therapeutics slipped 0.2% to US$26.29 after posting Q3 2026 numbers, a muted reaction for a biotech still deep in the development stage. On the surface, the latest quarter showed revenue of US$11.3 million alongside a basic loss per share of US$1.08, which keeps the focus firmly on cash burn and the road to potential launch rather than near term profit.

Short term traders see a stock that has drifted over the past three months. Long term holders are watching a very different story, centered on a forecast revenue growth profile and the valuation gap implied by discounted cash flow work.

Like the Stoke Therapeutics story but wary of a development stage biotech that is still loss making and focused on…